EN DE
Watch Tomocube Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Tomocube Inc (475960) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of Tomocube Inc stock KRW 16,812, price KRW 26,150, that is 35.7% below the price, quality 53 out of 100. Rating: strongly overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare KR

TI Tomocube Inc logo Thin data Nov 10, 2026

Tomocube Inc

475960 · KQ
Very expensive, in a downtrend

Our calculation puts a fair price 36% below what the stock costs today.

Low debt
Revenue last quarter +58% vs. a year ago.
Quality 53/100
Expensive Growth (revenue 3y +82.1 %/yr in KRW)
Mixed vs. peers (5/10)
Fair value 16,812 KRW · Strongly overvalued
Loss-making · -16.1% net margin (TTM)
Negative free cash flow
Narrow moat 10/100 · thin data
Thin data
Estimate
Watch Tomocube Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

66,300 KRW 10,070 KRW Fair Value 16,812 KRW Nov 2024 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

24‑month range 10,070 KRW – 66,300 KRW · fair‑value band 12,609 KRW – 21,015 KRW · the 26,150 KRW price screens above the 16,812 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.

Follow Tomocube in your weekly email

Every Wednesday you see whether Tomocube is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Tomocube, Inc. engages in the manufacture and sale of optical devices and medical equipment. Its holotomography (HT) products include HT-X1 for live-cell imaging and analysis; and HT-2H for 3D live cell imaging. The company also offers TomoAnalysis, a 3D image visualization and analysis software.

Show moreShow less

In addition, it provides accessories, such as HT-ready 96 well plates; TomoDish that is designed to accommodate both adherent and suspension cells; TomoChamber, a stage-top incubator designed for long-term live cell imaging; TomoPlate, an active vibration isolation system that enables users to capture images in a stable environment; and vessel holders, environmental controllers, and 3D controllers.

The company was founded in 2015 and is headquartered in Daejeon, South Korea.

Stock analysis

Tomocube Inc (475960) currently trades at 26,150 KRW, while our estimate is 16,812 KRW, 36% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: 12,609 KRW (bear) to 21,015 KRW (bull), the price of 26,150 KRW sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 53/100 (solid quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Tomocube Inc reported revenue of 11.3B KRW in FY2025 versus 1.6B KRW in FY2021, a compound +62.4%/yr. Reported net income was −4.8B KRW in FY2025.

Key figures

Market cap 407B KRW (≈ $305M) Small · P/S ratio 26.7 · EPS (TTM) −183.21 KRW · Net margin −16.1% · Return on equity −6.4% · Return on assets (EBIT) −22.9% (5-year average) · Operating margin −11.8% · Revenue (TTM) 15.2B KRW.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 10 out of 100 (low confidence).

What moves the price

The share trades about 61% below its 52-week high and 5% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −36%, 475960 screens richer than that median.

Fair Value

Bear 12,609 KRW Fair Value 16,812 KRW Bull 21,015 KRW
Price 26,150 KRW · Downside -35.7%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 53/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 9
How much profit the company makes from its sales and capital
Quality Growth 100
Are margins and returns getting better?
Cashflow 20
Do the profits arrive as real cash?
Financial strength 98
Debt, balance sheet and risk of trouble
Investment 41
Does it invest with discipline instead of growing at any price?
Low Volatility 0
How calm the share price moves, does not count
Price momentum 9
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 2
Distance to the 52-week high, does not count
New shares 67
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 44/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+90.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+82.1%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−394.4% (2021) → −49.3% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

475960 screens overvalued: fair value 36% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare Tomocube Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 849 stocks

Beats the industry median on 3/8 measures
Overall it trails its industry peers.
Valuation
Quality Score 53 · Top 25%
Fair Value upside −35.7% · Below median
Profitability
Return on assets −11.6% · Above median
Net margin (12 months) −16.1% · Below median
Operating margin (12 months) −11.8% · Below median
Growth and dividend
Revenue growth (quarter YoY) 58.0% · Top 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 10.49× · Priciest 25%
P/S (12 months) 26.73× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)100 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)100 · sector 96
DIVIDEND (yield)0 · sector 20

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $916.06 $1,275 +39% vs 475960
Samsung Biologics Co 207940 1,468,000 KRW 1,661,000 KRW +13% vs 475960
Vertex Pharmaceuticals Incorporated VRTX $547.89 $601.80 +10% vs 475960
Genmab A/S GMAB kr 3,581 kr 3,880 +8% vs 475960
argenx SE ARGX $971.55 $908.40 −7% vs 475960
CSL Limited CSL A$201.68 A$181.40 −10% vs 475960
Moderna, Inc MRNA $250.83 $158.70 −37% vs 475960
BeOne Medicines AG 6160 HK$252.20 HK$152.80 −39% vs 475960
Celltrion, Inc 068270 203,000 KRW 74,945 KRW −63% vs 475960
Royalty Pharma plc RPRX $69.45 $19.01 −73% vs 475960

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Tomocube Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Tomocube Inc Fair Value". https://www.fairvalue-calculator.com/stock/475960

Frequently asked questions

Is Tomocube Inc (475960) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is 16,812 KRW versus a price of 26,150 KRW, about 36% lower (overvalued).
What is the fair value of 475960?
Our estimate for Tomocube Inc is 16,812 KRW (as of Nov 10, 2026), built from audited fundamentals. The current price: 26,150 KRW.
What is the quality score of 475960?
Tomocube Inc has a Quality Score of 53/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Tomocube Inc (475960)?
Our calculated price target is the estimate of 16,812 KRW (as of Nov 10, 2026). Cautious scenario 12,609 KRW, optimistic scenario 21,015 KRW. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Tomocube Inc stock forecast for 2026?
Our estimate puts fair value at 16,812 KRW, about 36% lower versus a price of 26,150 KRW (overvalued). Cautious scenario 12,609 KRW, optimistic scenario 21,015 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Tomocube Inc (475960)?
Tomocube Inc reported trailing-twelve-month revenue of about 15.2B KRW (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of Tomocube Inc (475960)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Tomocube Inc it is 16,812 KRW per share (as of Nov 10, 2026), against a price of 26,150 KRW.
Is Tomocube Inc stock overvalued or undervalued in 2026?
As of Nov 10, 2026, 475960 trades above its calculated fair value: price 26,150 KRW, fair value 16,812 KRW, a gap of about −36% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 475960?
No. The price is what the market pays today (26,150 KRW); the fair value is what the company's own numbers justify (16,812 KRW). For Tomocube Inc the two are 9,338 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Tomocube Inc worth?
The market values Tomocube Inc at about 407B KRW (market capitalisation, as of Nov 10, 2026). Per share that is 26,150 KRW; our models calculate a fair value of 16,812 KRW per share.
What do the bullish and bearish scenarios say about 475960?
Our models span a range for Tomocube Inc: cautious scenario 12,609 KRW, base 16,812 KRW, optimistic 21,015 KRW per share (as of Nov 10, 2026, price 26,150 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Tomocube Inc (475960)?
Balance-sheet figures for Tomocube Inc (as of Nov 10, 2026): return on equity −6.4%. They feed the Quality Score of 53/100, which measures business quality independently of the share price.
How far is 475960 from its 52-week high?
Tomocube Inc trades at 26,150 KRW, about 61% below its 52-week high of 66,300 KRW and 5% above the low of 24,850 KRW (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of 16,812 KRW is for.
Which stocks are comparable to Tomocube Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Tomocube Inc stock attractive at the current price?
The data as of Nov 10, 2026: price 26,150 KRW, calculated fair value 16,812 KRW (−36%), Quality Score 53/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. Tomocube Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Tomocube Inc (475960)?
The closing price on Nov 10, 2026 was 26,150 KRW. Our estimate is 16,812 KRW, about 36% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Tomocube Inc right now?
The price sits above even our optimistic bull case (21,015 KRW). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (53/100) and above fair value, neither a clear bargain nor a standout compounder.

Key figures of Tomocube Inc

How large is the market capitalisation of Tomocube Inc (475960)?
The market capitalisation of Tomocube Inc is 407B KRW (≈ $305M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Tomocube Inc (475960)?
The price-to-sales ratio of Tomocube Inc is 26.7 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Tomocube Inc (475960)?
Earnings per share at Tomocube Inc are −183.21 KRW. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Tomocube Inc (475960)?
The net margin of Tomocube Inc is −16.1% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Tomocube Inc (475960)?
The return on equity (ROE) of Tomocube Inc is −6.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Tomocube Inc (475960)?
On an EBIT basis the return on assets of Tomocube Inc is −22.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Tomocube Inc (475960)?
The operating margin of Tomocube Inc is −11.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Tomocube Inc (475960)?
Revenue at Tomocube Inc is growing +58.0% versus a year earlier (3y avg +82.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Tomocube Inc (475960) generate?
The free cash flow of Tomocube Inc is −7.5B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
Free · no account needed

Watch Tomocube Inc in the live analysis

One click puts Tomocube Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.